{"id":"nai-pembrolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL3137343","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NAI stimulates the cGAS-STING pathway to promote interferon production and dendritic cell activation, priming innate immunity. Pembrolizumab blocks PD-1 on T cells to relieve immune checkpoint inhibition. Together, they aim to overcome tumor immunosuppression through both innate immune activation and adaptive T-cell checkpoint relief.","oneSentence":"NAI is a cGAS-STING agonist that activates innate immune signaling, combined with pembrolizumab, a PD-1 checkpoint inhibitor, to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:31.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 evaluation)"},{"name":"Melanoma and other checkpoint inhibitor-responsive cancers"}]},"trialDetails":[{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT05255666","phase":"PHASE2","title":"Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2023-07-31","conditions":"Triple Negative Breast Cancer, Brain Metastases","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NAI + Pembrolizumab","genericName":"NAI + Pembrolizumab","companyName":"ImmunityBio, Inc.","companyId":"immunitybio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NAI is a cGAS-STING agonist that activates innate immune signaling, combined with pembrolizumab, a PD-1 checkpoint inhibitor, to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 evaluation), Melanoma and other checkpoint inhibitor-responsive cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}